15 May, 2023.
A Western Sydney University (WSU) and Monash University comparative study has validated the Atmo Gas Capsule relative to the SmartPill when measuring gastric emptying time and colonic transit time in patients with gastroparesis and chronic constipation.
Dr Jerry Zhou, lecturer and clinical researcher at WSU School of Medicine, presented findings from the study in a poster presentation at Digestive Disease Week (DDW), held May 6-9 in Chicago.
1 May, 2023.
Atmo Biosciences today announced the appointment of renowned gastroenterologist Professor Eamonn Quigley as Chair of its Medical Advisory Board (MAB).
Prof. Quigley is David M. Underwood Chair of Medicine in Digestive Disorders and Chief of Gastroenterology and Hepatology at Houston Methodist Hospital in Texas. He is internationally known for his research on gastrointestinal motility disorders, particularly irritable bowel syndrome (IBS) and its link to the gut microbiome. As Atmo MAB Chair, Prof. Quigley will provide leadership and guidance regarding Atmo’s clinical trials portfolio.
“I am thrilled to have someone of Professor Quigley’s standing join our MAB as Chair,” said Atmo Biosciences CEO Malcolm Hebblewhite. “Eamonn is an internationally respected leader in gastroenterology. His ongoing research and thought leadership in the areas of motility and Small Intestinal Bacterial Overgrowth (SIBO) will be invaluable as we seek to develop these two key areas of focus in the U.S. and beyond.”
17 April, 2023.
Atmo Biosciences is strengthening its U.S. focus with the appointment of experienced medical device executive Chris Bertrand to the Atmo Board and establishment of a San Diego, California office.
Atmo Biosciences has raised A$8 million in a fully subscribed Series B funding round.
The raise was led by Japanese multinational company Otsuka Pharmaceutical, an existing strategic shareholder that took up more than its pro rata entitlement.
Atmo Biosciences is pleased to announce that it has successfully completed the audit of its Quality Management System to obtain ISO 13485:2016 accreditation.
Atmo Biosciences is pleased to announce that the European Patent Office and IP Australia have each granted patents related to key intellectual property for Atmo’s ingestible gas sensor capsule, providing coverage until 2037.
Atmo Biosciences is pleased to announce publication of a clinical study demonstrating strong agreement between data from Atmo’s world-first ingestible gas-sensing capsule and and a validated, FDA-cleared Wireless Motility Capsule (WMC), in determining transit metrics in healthy subjects.
Atmo Biosciences is pleased to announce that the US Patent and Trademark Office (USPTO) has granted the patent for Atmo’s ingestible gas sensor capsule.
Atmo Biosciences Limited, a digital health company developing the world’s first ingestible gas-sensing capsule for monitoring gut health and microbiome function, has made three key appointments, further building capability at the executive and Board levels.